A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM)

被引：0
|
作者：
Sullivan, Ryan J.
Ibrahim, Nageatte
Lawrence, Donald P.
Aldridge, Julie
Hodi, F. Stephen
Flaherty, Keith
Conley, Christine
DeNoble, Sarah
Mier, James Walter
Cho, Daniel C.
Atkins, Michael B.
McDermott, David F.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Int Beast Canc Study Grp Stat Ctr, Boston, MA 02115 USA
[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA
[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[6] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9076
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A MULTICENTRE, PHASE II STUDY OF CP-4055 IN COMBINATION WITH SORAFENIB IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA
    Dueland, S.
    Aamdal, S.
    Nyakas, M.
    Lundgren, L.
    Wagenius, G.
    Ljuslinder, I.
    Stierner, U.
    Gaullier, J.
    Nilsson, B. I.
    Rasch, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 245 - 246
  • [22] The combination of bortezomib (BOR) and decitabine (DEC): A phase I trial in patients (pts) with acute myeloid leukemia (AML) targeting FLT3 expression
    Schwind, Sebastian
    Bium, William
    Liu, Shujun
    Tarighati, Somayeh Samadzadeh
    Geyer, Susan
    Klisovic, Rebecca
    Eisfeld, Ann-Kathrin
    Walkers, Alison
    Whitman, Susan
    Ramasamy, Santhanam
    Wu, Yue-Zhong
    Jacob, Samson
    Caligiuri, Michael
    Grever, Michael
    Perrotti, Danilo
    Byrd, John
    Bloomfield, Clara
    Garzon, Ramiro
    Marcucci, Guido
    CANCER RESEARCH, 2012, 72
  • [23] Survivorship experience for patients (pts) with metastatic melanoma (MM) on immunotherapy (IT)
    Lai-Kwon, Julia Elizabeth
    Khoo, Chloe Chia Hoey
    Lo, Serigne
    Milne, Donna
    Mohamed, Mustafa Abdi
    Raleigh, Jeanette
    Smith, Kortnye Maureen
    Sandhu, Shahneen Kaur
    Jefford, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Phase I/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma: Looking for predictive markers of efficacy
    Robert, C.
    Chaput, N.
    Lassau, N.
    Auperin, A.
    Koscielny, S.
    Hollville, E.
    Lazar, V.
    Lacroix, L.
    Soria, J.
    Mateus, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Combination of brain radiotherapy (RT) and immunotherapy (IT) in a single Institution cohort of patients (pts) with metastatic melanoma (MM)
    Galli, G.
    Cavalieri, S.
    Di Guardo, L.
    Cimminiello, C.
    Corti, F.
    Nichetti, F.
    Garcia, M.
    Tana, S.
    Fallai, C.
    de Braud, F.
    Platania, M.
    Del Vecchio, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Phase I study of ipilimumab (IPI) with biochemotherapy (BCT) for chemonaive patients with metastatic melanoma (MM).
    Amaria, Rodabe Navroze
    Bassett, Roland L.
    Simpson, Lauren
    Delaney, Frances
    Hwu, Patrick
    Kim, Kevin
    Hwu, Wen-Jen
    Patel, Sapna Pradyuman
    Glitza, Isabella Claudia
    Davies, Michael A.
    Woodman, Scott Eric
    Yee, Cassian
    Bedikian, Agop Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM)
    Kim, K. B.
    Flaherty, K. T.
    Chapman, P. B.
    Sosman, J. A.
    Ribas, A.
    McArthur, G. A.
    Amaravadi, R. K.
    Lee, R. J.
    Nolop, K. B.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Iyer, Renuka
    Sonti, Sahithi
    Mahalingam, Devalingam
    Mukherjee, Sarbajit
    Chakraborty, Sayan
    Attwood, Kristopher
    George, Anthony
    Maguire, Orla
    Minderman, Hans
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
  • [29] Phase I study of paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Kummer, G.
    Strumberg, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Phase I study with paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Heuer, V
    Kummer, G.
    Strumberg, D.
    ONKOLOGIE, 2011, 34 : 110 - 110
12345